Airway diseases such as allergic asthma and rhinitis are charactized by a T Helper 2 response.
Introduction
The development of allergic airway diseases, such as asthma and allergic rhinitis, is determined by numerous factors such as genetic predisposition to develop atopy or hyperresponsiveness, but also by exposure to allergens, infections and pollution. The past several decades, we have seen many break-throughs in understanding the immunological mechanisms initiating and mediating allergic airway responses. Despite this progress, mainstream therapy still consists of disease control with anti-inflammatory glucocorticoidbased drugs, bronchodilators and antihistamines. Although these drugs relieve symptoms and are sufficient to treat the majority of patients, they do not cure the disease. Therefore, the challenge remains to develop safe new therapeutics that could resolve allergic airway diseases. Several approaches have been taken in the search of new therapies. Allergenspecific immunotherapy (SIT), which induces immunological tolerance through repeated exposure to allergens, has gained a lot of interest, despite the long treatment period and risk for anaphylaxis. Also many efforts have been made using specific inhibitors or blocking antibodies to target specific mediators (e.g. IgE and various cytokines) that are implicated in allergic airway diseases [1, 2] . Despite all existing therapies, there are still a considerable number of patients with a poor quality of life due to uncontrolled or partially controlled asthma [3] , that could benefit from additional treatment options. Gene therapy could provide a novel and effective therapeutic alternative by targeting crucial steps in the development of allergic diseases, with the potential of local treatment with long-lasting effects. Gene therapy, which treats or eliminates the causes of disease by gene transfer or gene silencing, has gained more and more interest since the first attempts in the early nineties. Whereas initial efforts for gene therapy were largely concentrated in diseases without effective alternative therapies (e.g. cancer and inherited disorders such as cystic fibrosis), recent developments have also focused on other illnesses, including asthma and allergic rhinitis. In contrast to cystic fibrosis, which is a monogenic disorder related to mutations in the CFTR gene, allergic airway diseases are polygenic disorders with an additional considerable environmental contribution, implicating that aiming at the "genetic predisposition" in asthmatics or allergic rhinitis patients by gene therapy is unrealistic. However, targeting specific mediators or targeting the functionality of crucial cells in the disease pathogenesis may become a future approach to provide an additional treatment for e.g. severe, uncontrolled asthmatics. In this review, we report on the techniques and gene targets that have been recently investigated for their therapeutic potential in treating allergic airway diseases, with focus on in vivo observations.
Mechanisms of allergic airway disease
The immunological mechanisms initiating and mediating allergic airway responses are already well understood [4] (Fig 1) . Professional antigen presenting cells (predominantly dendritic cells) capture allergens and transport them to the lymph nodes, followed by antigen presentation to naïve T-cells. This interaction selects the T H 2 pathway in which transcription factor GATA-binding protein 3 (GATA-3) controls the expression of several cytokines, including IL-4, IL-5, IL-9 and IL-13. These cytokines are important for isotype class Reactive oxygen species (ROS) from eosinophils or mononuclear phagocytes can contribute to airway inflammation through the induction of cytokines, chemokines and adhesion molecules via the NF-κB pathway and mitogen-activated protein kinase (MAPK) cascades in macrophages and epithelial cells. As the T H 2-inflammation continues, goblet cell hyperplasia and airway wall remodeling occur by action of IL-13, in coorporation with several growth factors.
In the past, allergic airway responses were mainly explained by an imbalance between T H 1 (IFNγ-producing) and T H 2 (IL-4, IL-5, IL-13-producing) cells. With the discovery of regulatory T-cells (T Regs , producing inhibitory IL-10 and TGF-β) and IL-17 secreting T H 17 cells (implicated in neutrophilic inflammation in asthma [5] ), the picture has become more complex, but this also offers new opportunities for intervention (Fig 1) .
Gene therapy in upper and lower airways
Advances in the field of gene transfer to the airways have emerged from the need to find new therapies for cystic fibrosis. Numerous efforts were made to achieve pulmonary transgene expression [6, 7] . Gene transfer to the lung can occur by the use of helper-dependent adenovirus vector, adeno-associated virus vectors, lentiviral vectors, or the use of naked DNA. Each of these systems has had its successes and failures, but sustained efforts for improvement have contributed to our knowledge to acquire prolonged transgene expression in the lungs (reviewed in [8, 9] ). Moreover, the technological developments for DNA-transfer have also been of interest for strategies aimed at inhibition of gene expression. In contrast to other organs, the respiratory system is relatively easily accessible for treatment by nebulizer technology, so delivery of gene transfer vectors is in principle simple. However, many technical challenges exist including stability of vectors, ability to reach target cells, transfection efficiencies and achieving long term-expression without initiating immune responses (neutralizing antibodies) towards viral gene targeting vectors [10, 11] . Also the presence of mucus and pulmonary inflammation can complicate gene transfer. To treat chronic respiratory allergic diseases by gene therapy, a long-term transgene expression or gene silencing is a prerequisite. Respiratory epithelial cells are slowly dividing or terminally differentiated, rendering them as good candidates to achieve prolonged transgene expression or prolonged gene silencing. However, also inflammatory cells are important targets and stem cells or progenitor populations that can self-renew indefinitely are potential targets for achieving long-term gene expression [12, 13] . Gene therapy can occur by direct delivery of targeting agents to the lung, resulting in a general pulmonary distribution and potential targeting of different cell types (but mainly epithelial cells). Alternatively, ex vivo therapy on specifc cells (e.g, dendritic cells or T-cells) resulting in cell-based gene delivery can be considered.
Disease control by gene-silencing techniques
RNA-based gene silencing strategies that dampen the expression of disease-causing genes have therapeutic potential in controlling allergic airway diseases [14] . Endogenous miRNAs have recently gained a lot of interest [18] . They fulfill important functions in many biological processes through post-transcriptional (down)regulation of gene expression. A single miRNA may control translation of hundreds of genes, so it is very likely that miRNAs contribute to disease. Blocking miRNA expression could thus offer therapeutic possibilities. Antagomirs (synthetic analogs of miRNA) that induce a specific and long-lasting silencing of miRNAs, are potential innovative drugs [19] .
An important point of concern when using gene silencing techniques (antisense oligonucleotides and siRNA) is the potential to generate off-target effects. These are effects resulting from the recognition of foreign oligonucleotides (CpG-containing DNA, single stranded RNA or double stranded RNA) by Toll-like receptors (TLRs) that are part of the host's innate defence mechanism. TLRs detect danger signals of microbial origin (e.g. viral RNA or bacterial DNA), resulting in a T H 1 inflammation, including proinflammatory cytokine and IFN-γ production. Therefore the occurrence of side effects of gene silencing techniques needs to be evaluated with long term studies [20] . Also delivery systems for antisense molecules or siRNA (e.g. cationic lipids) can enhance their immunostimulatory properties, and the stabilizing phosphorothioate backbone has a dose-limiting toxicity [21] . A second point of concern is duration of the gene silenceng effects. For antisense oligonucleotides these effects last up to 1 week, so repeated treatment will be needed. For siRNA, long-lasting effects up to 8 weeks have been described [22] .
Control of allergic airway disease by targeting T H 2-cytokines and inflammatory mediators
Considering the key role of T H 2-cytokines in orchestrating allergic inflammation, they are important therapeutic targets. Cytokine inhibitors in the form of monoclonal antibodies or small molecule antagonists have been developed to treat asthma, with many still being in preclinical development. Until now, the success of this approach has been limited, with very few therapies reaching clinical trials (reviewed in [23, 24] ). Besides the practical issues of reaching the optimal dose resulting in clinical benefit without detrimental side effects, targeting a single mediator or receptor may be insufficient, considering the numerous cytokines and redundancy of pathways involved. However, especially in specific asthma phenotypes with high levels of these mediators (e.g. IL-5, IL-13 or IL-4), these therapies could be beneficial and targeting mediators by gene therapy could provide a promising alternative for the existing antibody therapies (Fig 1 and Table 1 ).
It has recently been demonstrated that anti-IL-5 antibody therapy reduces exacerbation rate in a subset of severe asthma patients with evidence of eosinophilic airway inflammation and recurrent exacerbations [25] . Several approaches are taken to target IL-5 via gene therapy in preclinical studies. Intratracheal administration of IL-5 siRNA-expressing lentivirus could reduce airway hyperresponsiveness (AHR), cellular infiltration of lung tissue, eotaxin levels in bronchoalveolar lavage (BAL) and pulmonary IL-5 mRNA in a mouse model of allergic inflammation [26] (Table 1) . Systemic administration of antisense IL-5 or antisense IL-4, transferred by a recombinant adeno-associated virus has been shown to reduce IL-5 or IL-4 expression, allergic inflammation and airway remodeling in a rat model [27] [28] [29] . However, for achieving major clinical effects, it could be of more interest to target several mediators or signaling pathways. Blocking both IL-4 and IL-13 signaling through an antisense oligonucleotide against IL-4 Receptor α-chain (IL-4R-α) reduced several hallmarks of asthma in a mouse model [30] . A Phase I study testing nebulized AIR645 (antisense IL-4R-α blockade, Altair Therapeutics) in healthy volunteers and mild asthmatics demonstrated it is well tolerable, leads to a low systemic exposure and has the potential to be used for oneweekly treatment [31, 32] . Another important Phase IIa trial demonstrated that inhalation of TPI ASM8 (Topigen Pharmaceuticals) containing two modified phosphorothioate antisense oligonucleotides that block CCR3 (receptor for eotaxin) and the common β chain (βc) of the IL-3-, IL-5-and GM-CSF-receptors could reduce both allergen-induced airway eosinophilia and the early asthmatic response in mild atopic asthmatic patients [33] . Recently, a Phase IIa study investigating the efficacy and safety of four escalating dose regimens of TPI ASM8 in patients with allergic asthma has been completed, but the results are awaited [34] .
Control of allergic airway disease by targeting crucial transcription factors
An even more appealing approach to reduce allergic immune responses is targeting transcription factors that elicit T H 2-responses (Fig 1 and Table 1 ).
STAT: The signal transducer and activator of transcription (STAT) family of transcription factors are implicated in many signalling processes. They play an important role in T-cell differentiation by activating the typical T-cell transcription factors (T-BET, GATA-3, FoxP3
and RORγτ) and are thus potential therapeutic targets (Fig 1, [35] ). Activation of STAT6 is critical for the differentiation of naïve T-cells into T H 2 effector cells. STAT6 also regulates IL-4-and IL-13-induced production of T H 2-chemokines (including eotaxin) from airway epithelial cells, fibroblasts and smooth muscle cells [36] . During allergic pulmonary inflammation, STAT6 is required for T H 2 lymphocyte and eosinophil homing to the airways and STAT6 expression in lung epithelial cells drives mucus production and the development of airway hyperresponsiveness [37, 38] . Therefore, local inhibition of STAT6 expression provides a rationale for therapeutic intervention in bronchial asthma. In vitro studies have demonstrated that expression of eotaxin mRNA by IL-4/IL-13-pre-activated human lung epithelial cells could be abrogated by eliminating STAT6 expression through STAT6 siRNA.
This indicates that mucosal cells in ongoing chronic asthma-associated lung-inflammation could be responsive to this approach [39] . In an in vivo murine model, intranasal administration of naked siRNA against STAT6 to sensitized animals right before and during allergen challenge significantly inhibited the development of allergen-induced airway inflammation, goblet cell hyperplasia and airway hyperresponsiveness [40] . Also in an in vivo allergic rhinitis model, the therapeutic potential to target STAT-6 was demonstrated [41] .
These preclinical studies suggest that STAT6 is indeed a promising target for treatment of allergic airway diseases, but so far no clinical trials have been published using this approach.
GATA-3:
The therapeutic potential of blocking GATA-3, the T H 2 differentiation transcription factor that regulates the expression of IL-4, IL-5 and IL-13, was already demonstrated a decade ago in a mouse model of allergic inflammation using antisense oligonucleotides [42] .
Recently, short hairpin RNA and GATA-3 specific DNAzyme could also attenuate allergic inflammation in a mouse model [43, 44] . DNAzyme was compared with other gene silencing techniques and proved to be the most efficient without eliciting off-target effects, suggesting this technique could offer new opportunities [45] .
NF-κβ: NF-κβ is a transcription factor that is believed to play an important role in many acute and chronic inflammatory diseases, including asthma [46] . NF-κβ is expressed in numerous cell types and controls the expression of many pro-inflammatory genes, leading to the synthesis of cytokines, adhesion molecules, growth factors and enzymes. Targeting of NF-κβ using p65 antisense oligonucleotides has been performed in vivo in an ovalbumin (OVA) murine model several years ago [47] . However as far as we are aware, no recent major breakthroughs were reported about transfering this knowledge to the clinic.
Targeting transcription factors with decoy oligonucleotides: An alternative method to inhibit target gene expression is the use of decoy oligonucleotides. These short double stranded synthetic oligonucleotides contain transcription factor binding sites that are recognized by nuclear transcription factors. Binding to decoy oligonucleotides, prevents transcription factors to bind efficiently the consensus sequences of their target genes, thus preventing target gene expression. Beneficial effects of decoy oligonucleotides blocking NF-κβ, activator protein-1 and STAT-1 on experimental asthma in mice were demonstrated several years ago [48] [49] [50] . A recent study using a decoy oligonucleotide blocking both STAT-1 and STAT-3 transcription factors reduced allergic inflammation and pulmonary CD40 expression in a rat model of OVA-induced allergic inflammation [51] .
Control of allergic diseases by targeting microRNA
As mentioned before, miRNAs control the translation of many genes and could thus be implicated in the regulation of asthma and allergen-induced T H 2 responses [52, 53] . The importance of miRNAs in several pulmonary inflammatory diseases is currently a hot topic, and miR-21, miR-126 and miR-133a have been associated with asthma pathogenesis [54] . A role for miR-126 was demonstrated in a house dust mite model of allergic inflammation, with the expression of miR-126 being TLR4/MyD88-dependent. More importantly, intranasal application of antagomirs that block miR-126, suppressed AHR and several hallmarks of allergic airway inflammation, demonstrating this approach may be a useful strategy to treat disease [55] .
Targeting antigen presenting cell-T-cell interactions or T H 2 cell function
Considering the key role for dendritic cells in initiating and maintaining T H 2 responses, they provide an attractive target to treat allergic airway diseases [56] . Optimal induction of T-cell responses requires more than antigen presentation by dendritic cells. The duration and strength of the dendritic cell/T-cell interaction also needs to be sufficient to induce T-cell division and differentiation. Costimulatory molecules such as CD80, CD86 and CD40 can provide these additional signals. Targeting CD86 by inhaled antisense oligonucleotides suppressed CD86 expression on dendritic cells, macrophages and eosinophils and reduced AHR, pulmonary inflammation, mucus production and BAL eotaxin levels in a murine asthma model [57] . Targeting CD40 by siRNA reduced allergic symptoms, eosinophilic inflammation, OVA-specific T-cell responses and immunoglobulin production in a mouse model of allergic rhinitis, by inhibiting both dendritic cell and B-cell functions and by inducing a regulatory T-cell response [58] . Moreover, targeting solely the dendritic cell, by injecting in vitro CD40-silenced allergen-specific dendritic cells in this model, could improve established allergic rhinitis and facilitated the generation of allergen-specific regulatory Tcells, thus linking gene therapy with allergen-specific therapy [59] . This is a promising and hopeful achievement; however, implementation in the clinic still has to be investigated.
Besides exploring the dendritic cell/T-cell interaction, T-cell functionality can also be targeted. A recent report demonstrated that T H 2 cells selectively express voltage-dependent calcium (Ca v 1)-related channels, making them a potential and selective target for therapy.
Inhibition of these channels by antisense oligonucleotides was effective in active experimental asthma, preventing airway inflammation, T H 2-cell activation and AHR, without affecting T H 1-responses [60] .
Targeting kinases
Many kinases are implicated in the pathogenesis of allergic airway diseases. Kinases such as p38 mitogen-activated protein (MAP) kinase and NF-κβ are crucial in regulating the expression of inflammatory genes that are overexpressed in asthma, whereas the phosphoinoside-3-kinase (PI3K) is implicated in reduced steroid responsiveness. Spleen tyrosine kinase (Syk) is involved in the activation of mast cells and other immune cells.
Therefore, many potent small molecule inhibitors of kinases have therapeutic potential.
However, since kinase signaling transduction pathways are present in many cell types, systemic administration implicates the risk of side effects. The development of inhaled inhibitors may thus result in a better therapeutic index [61] . Gene therapy, with a specific and local inhibition of these kinases in the airway compartment could offer a future possibility for disease intervention. The successful inhibition of Syk kinase by aerosolized antisense oligonucleotides in a mouse model provides the proof of principle for such a strategy [62] and the development of more efficient siRNA is underway [63] . Sphingosine kinase (SphK) mediates intracellular sphingolipid levels after activation of various membrane receptors (e.g.
FcεRI and FcγRI receptors, TNF-α receptor). SphK is important in lymphocyte and
eosinophil migration and mast cell degranulation. Blocking of SphK by siRNA reduced pulmonary inflammation, T H 2 cytokines and allergen-specific IgE in a murine model of allergic asthma [64] .
Besides kinases, recently a role for acidic mammalian chitinase (AMCase) in allergic airway diseases has been proposed. Blocking of AMC (expressed in lung epithelial cells and alveolar macrophages) by RNA interference improved allergic airway inflammation and hyperresponsivesness in a murine model [65] .
Disease control by transgene overexpression to counteract T H 2 inflammation
Beyond using gene silencing techniques to target factors that are upregulated during allergic airway inflammation, another therapeutic approach is transgenic expression of cytokines, immunodulatory factors or transcription factors that inhibit the inflammatory disease processes. In the past, reducing allergic airway inflammation in mice has been successful by overexpressing TGF-β, IFN-γ, IL-10, IL-18 and IL-1 receptor antagonist (for review see [66] ). Below, the recent developments are described. Intratracheal administration of the IL-4RA gene on a plasmid has attenuated airway inflammation and regulated the T H 1/T H 2 balance in a mouse model [67] .
IL-12 and IL-10: IL-12 directs naive precursor T-cells towards T H 1 differentiation, whereas IL-10 inhibits the expression of many pro-inflammatory cytokines and chemokines and is the main cytokine produced by T Reg cells (Fig 1) . Both intramuscular injection of IL-12-plasmid and intratracheal application of combined adenovirus expressing IL-10 and IL-12 have reduced the airway inflammation and AHR in mouse models [68, 69] . The combined IL-10 and IL-12 expression prevented adverse effects resulting from sole IL-12 overexpression [70] . demonstrating that delivering siRNA to the airways in vivo is feasible. Also the report in humans using antisense technology to block the CCR3 and βc-receptors in mild asthmatics [74] gave promising results.
In the near future, we do not expect gene therapy to become an alternative for standard corticosteroid-based therapies, that work well for most asthmatic patients. However, for certain asthma subtypes, severe asthmatics with a particular overexpression of a specific cytokine or mediator, that do not receive sufficient clinical benefit from current existing therapies, gene therapy may become an interesting add-on therapy with long-lasting effects, better control of symptoms and reduction of medication. In conclusion, although gene therapy is currently not yet a therapeutic option, recent progress makes us hopeful that for difficult to treat and uncontrolled asthma patients, gene therapy may provide the answer for the future. 
